Sweden · Delayed Price · Currency is SEK Essity AB Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw positive organic sales growth, strong volumes in most segments, and resilient margins despite cost inflation. Price increases and cost-saving programs are underway to offset higher COGS, with further margin improvement expected as integration and innovation continue.
-
Leadership is accelerating strategy execution with a decentralized structure, portfolio review, and cost-saving initiatives. Business units focus on high-value segments, innovation, and resilience, with price increases and reinvestment in growth to navigate current market challenges.
-
A strategic review of the Consumer Tissue business is underway, with a focus on shifting the portfolio toward higher value-added segments and accelerating profitable growth. Clear financial targets and cost-saving initiatives support increased investment in innovation, digitalization, and sustainability, while each business area pursues tailored growth strategies.
-
Organic sales and volume growth, improved margins, and strong cash flow marked Q1 2026, supported by a major North American acquisition and a SEK 3 billion share buyback. Input cost inflation and selective price increases are expected to shape results in H2.
-
Strong brands and innovation drive growth in high-margin hygiene and health categories, supported by a decentralized structure and targeted acquisitions. Cost-saving programs and digital transformation underpin efficiency, while disciplined capital allocation supports dividends and buybacks.
Fiscal Year 2025
-
Profit margins improved across all business areas in Q4 2025, despite negative organic sales growth due to price reductions. Strategic acquisitions, strong cash flow, and product innovation supported market share gains and a proposed 6% dividend increase.
-
The acquisition of established feminine care brands in North America for $340 million expands market presence, adds scale, and is expected to deliver $30 million in cost synergies by year two. Management aims to revitalize the brands through innovation and brand building, targeting long-term growth and margin improvement.
-
Organic sales grew 0.9% year-over-year, with record gross margins and profit above SEK 5 billion. A major reorganization and SEK 1 billion cost saving program were announced to accelerate growth, with savings to be reinvested in high-return areas.
-
The conference highlighted a strategic focus on high-margin segments, innovation, and operational efficiency, with ambitions to outperform market growth and maintain strong financial targets. Leadership emphasized customer centricity, global expansion, and continued M&A, aiming for profitable growth and stability.
-
Organic sales grew 1.9% year-over-year, with strong pricing and innovation offsetting weak volume growth in a challenging market. Profitability was stable but pressured by higher costs, while strategic segments and new product launches drove performance.
-
Solid Q1 performance with higher sales, strong cash flow, and flat volumes, driven by price increases and growth in high-margin categories. Tariff impact remains limited, while cost savings and a SEK 3 billion share buyback support a robust outlook for profitable growth.
-
Strong 2024 results were driven by innovation, portfolio reshaping, and margin expansion. The group targets over 3% organic sales growth and 15%+ margin, with a focus on innovation, M&A in Health & Medical, and expansion in North America and Asia. Share buybacks and rising dividends remain key capital allocation tools.
Fiscal Year 2024
-
Record 2024 results with SEK 146 billion in sales and over SEK 20 billion operating profit, driven by strong volume growth, innovation, and portfolio optimization. Margins were pressured in Q4 by currency and cost inflation, but outlook for 2025 remains positive with increased CapEx and A&P to support profitable growth.
-
The company targets over 3% organic sales growth and 15%+ EBITDA margin by focusing on high-margin categories, innovation, and operational excellence. Strong brands, digitalization, and sustainability drive above-market growth, while disciplined capital allocation supports recurring share buybacks and targeted M&A.
-
Profitable growth achieved with higher market shares and volumes, strong EBITA margin, and record cash flow. Cost savings and pricing agility offset raw material headwinds, while share buybacks and sustainability initiatives advanced. Net debt and leverage remain low.
-
Record EBITA and margin improvements were achieved across all business areas, with strong underlying volume growth and robust cash flow. Price increases in consumer tissue will mainly impact Q4 to offset rising input costs, while a SEK 3 billion share buyback program was launched.
-
Raised financial targets to over 3% organic sales growth and 15% EBITA margin, supported by a SEK 3 billion share buyback and a focus on high-margin growth. Operational improvements, innovation, and targeted M&A underpin the strategy, with a strong balance sheet post-Vinda divestment.
-
The business is delivering strong financial results, driven by leading market positions, operational efficiencies, and a strategic shift toward higher-margin segments. Growth is supported by demographic trends, innovation, and enhanced pricing power, while a strong balance sheet enables flexibility for future investments and acquisitions.